Myasthenia Gravis

Soliris Approved to Treat Generalized Myasthenia Gravis

By October 24, 2017

The FDA based its approval of the extended indication for Soliris on comprehensive clinical data from the Phase 3, randomized, double-blind, placebo-controlled, multicenter REGAIN study (ECU-MG-301).

Thymectomy Tied to Multiple Benefits in Myasthenia Gravis

August 12, 2016

Thymectomy improves clinical outcomes over a three-year period in patients with nonthymomatous myasthenia gravis, according to research published in the Aug. 11 issue of the New England Journal of Medicine.

Impax Launches Generic Mestinon Timespan Tabs

By September 17, 2015

Impax announced that the Food and Drug Administration (FDA) has approved Pyridostigmine Bromide Extended-Release Tablets, the generic version of Valeant's Mestinon Timespan.

Drisapersen Granted Breakthrough Therapy for Rare Neuromuscular Disease

July 01, 2013

The FDA has granted Breakthrough Therapy designation to drisapersen, an exon-51 skipping compound for the potential treatment of patients with Duchenne Muscular Dystrophy, a lethal form of muscular dystrophy.

Vitamin D Linked to Mitochondrial Oxidative Function

March 19, 2013

Findings in a small group of patients with very low vitamin D levels show that muscle efficiency significantly improves when vitamin D status is improved.

Corticorelin Acetate Has Steroid-Sparing Effect in Brain Cancer

February 06, 2013

Corticorelin acetate (CrA) administration to patients with peritumoral brain edema (PBE) allows the reduction of steroid doses and is associated with reduced incidence and severity of steroid-induced myopathy and other steroid-related adverse effects.

Orphan Drug Designation for Myostatin Inhibitor for Muscular Dystrophy

December 12, 2012

Milo Biotechnology announced that AAV1-FS344 has been granted Orphan Drug designation from the FDA for the treatment of Becker and Duchenne muscular dystrophy.